title: A UK audit of screening for the metabolic side effects of antipsychotics in community patients.
abstract: Reviews of the association between psychotic disorder, the metabolic syndrome, diabetes, and antipsychotic drugs conclude that there is a need for active, routine physical health screening of patients' prescribed antipsychotic drugs. From published guidelines, we derived the audit standard that all such patients should, as a minimum, have their blood pressure, body mass index (BMI) (or other measure of obesity such as waist circumference), blood glucose (or HbA(1c)), and plasma lipids measured at least once a year. We conducted an audit of the clinical records of 1966 eligible patients under the care of 48 multidisciplinary, assertive outreach clinical teams in 21 mental health services across the United Kingdom. This revealed a recorded measurement within the previous year for blood pressure in 26% of the patients, obesity in 17%, blood glucose (or HbA(1c)) in 28% and plasma lipids in 22%, with all 4 measures documented in 11%. In the total national sample, 6% had a documented diagnosis of diabetes, 6% hypertension, and 6% dyslipidemia. Extrapolating from the prevalence of these disorders in similar populations suggests that for every patient with a known diagnosis of diabetes, another had not been recognized, for every known case of hypertension, 4 had been missed, and for every known case of dyslipidemia, 7 had been missed. The responses of the clinical teams to a questionnaire yielded information on obstacles to screening in routine practice, revealing uncertainty about whose responsibility this was, a lack of confidence about the interpretation of abnormal screening results, and limited access to basic equipment.
authors.affiliation: Department of Psychological Medicine, Imperial College Faculty of Medicine, Charing Cross Campus, London W6 8RP, UK. t.r.barnes@imperial.ac.uk
authors.forename: Thomas R E
authors.initials: TR
authors.lastname: Barnes
authors.forename: Carol
authors.initials: C
authors.lastname: Paton
authors.forename: Mary-Rose
authors.initials: MR
authors.lastname: Cavanagh
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Hancock
authors.forename: David M
authors.initials: DM
authors.lastname: Taylor
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000378:metabolism*; D003156:Community Mental Health Services / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000379:methods*; D012559:Schizophrenia / Q000188:drug therapy / Q000453:epidemiology / Q000378:metabolism; D006113:United Kingdom / Q000453:epidemiology
chemical_list: D014150:Antipsychotic Agents